CHNA VS CFRX Stock Comparison

PerformanceTechnicalsVolatilityAnalyst Price TargetsEarningsProfit
PerformanceTechnicalsVolatilityAnalyst Price TargetsEarningsProfit

Performance

CHNA
10/100

CHNA returned -3.63% in the last 12 months. Based on SPY's performance of 12.05%, its performance is below average giving it a score of 10 of 100.

CFRX
10/100

CFRX returned -98.02% in the last 12 months. Based on SPY's performance of 15.09%, its performance is below average giving it a score of 10 of 100.

Technicals

CHNA
11/100

CHNA receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

CFRX
14/100

CFRX receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Volatility

CHNA
60/100

CHNA has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.

CFRX
32/100

CFRX has had a lower than average amount of volatility over the last 12 months giving it a score of 32 of 100.

Analyst Price Targets

CHNA

"Analyst Price Targets" not found for CHNA

CFRX
88/100

2 analysts offer 12-month price targets for CFRX. Together, they have an average target of 0, the most optimistic target put CFRX at 0 within 12-months and the most pessimistic has CFRX at 0.

Earnings

CHNA

"Earnings" not found for CHNA

CFRX
10/100

CFRX has missed earnings 8 times in the last 20 quarters.

Profit

CHNA

"Profit" not found for CHNA

CFRX
13/100

Out of the last 20 quarters, CFRX has had 3 profitable quarters and has increased their profits year over year on 1 of them.

All score calculations are broken down here to help you make more informed investing decisions

Loncar China BioPharma ETF Summary

Nasdaq / CHNA
The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.

ContraFect Corporation Summary

Nasdaq / CFRX